Enochian Biosciences, Inc. (NASDAQ:ENOB) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 1,440,000 shares, a growth of 28.6% from the March 31st total of 1,120,000 shares. Currently, 10.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 283,700 shares, the days-to-cover ratio is currently 5.1 days.
Shares of ENOB stock traded down $0.23 during midday trading on Tuesday, reaching $3.53. 221,124 shares of the company were exchanged, compared to its average volume of 250,469. Enochian Biosciences has a 12 month low of $2.60 and a 12 month high of $13.43. The company’s 50 day moving average price is $3.47 and its two-hundred day moving average price is $3.34. The company has a quick ratio of 7.29, a current ratio of 7.29 and a debt-to-equity ratio of 0.04.
Enochian Biosciences (NASDAQ:ENOB) last released its quarterly earnings results on Tuesday, February 16th. The company reported ($0.06) EPS for the quarter.
Several hedge funds have recently added to or reduced their stakes in the business. Barclays PLC raised its holdings in shares of Enochian Biosciences by 112.1% in the 4th quarter. Barclays PLC now owns 13,401 shares of the company’s stock worth $39,000 after purchasing an additional 7,082 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Enochian Biosciences by 24.2% in the 4th quarter. Rhumbline Advisers now owns 14,932 shares of the company’s stock worth $44,000 after purchasing an additional 2,905 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Enochian Biosciences in the 4th quarter worth approximately $53,000. Marshall Wace LLP bought a new stake in shares of Enochian Biosciences in the 1st quarter worth approximately $60,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Enochian Biosciences in the 4th quarter worth approximately $67,000. Institutional investors own 5.11% of the company’s stock.
Enochian Biosciences Company Profile
Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine.
Featured Article: How to Calculate Compound Annual Growth Rate (CAGR)